Effect of early use of evolocumab in combination with statin on lipids, lipid ratio and cardiac function in patients with acute coronary syndromes
ZHU Enhui, CHEN Yujie, Aikedai·AIHEMAITIJIANG, FEI Shasha, YANG Rujia, WANG Juan
2026, 46(10):
1397-1401.
doi:10.16352/j.issn.1001-6325.2026.10.1397
Asbtract
(
27 )
PDF (748KB)
(
5
)
References |
Related Articles |
Metrics
Objective To investigate the lipid-lowering efficacy and safety of early evolocumab administration in ACS patients. Methods A total of 311 ACS patients (Jan-Dec 2023) receiving atorvastatin (20 mg QN) were randomized: observation group (Obs, n=213) started evolocumab within 48 h of hospital admission; control group (Ctrl, n=98) started post-PCI. Lipid profile (LDL-C, TC, TG, ApoB, HDL-C, ApoA-Ⅰ), LDL-C goal rate (<1.4 mmol/L),the lipid ratios (TC/HDL-C, TG/HDL-C, LDL-C/HDL-C, ApoB/ApoA-Ⅰ), lipid variability (SD, CV, cVIM),cardiac function (LVEDD, LVESD, LVMI, LVEF), and liver/kidney function were assessed at discharge and 1, 3, 6 months. Results At 1 month, lipids decreased significantly vs baseline in both groups (P<0.05). Obs showed greater reductions in LDL-C, TC, TG, ApoB vs Ctrl (P<0.05). LDL-C goal rate increased over time, consistently higher in Obs (P<0.05). Lipid ratios decreased more in Obs (P<0.05). In both groups, LVEDD, LVESD, and LVMI decreased, while LVEF increased; the Obs group showed significantly greater improvements(P<0.05) and milder liver/kidney impairment(P<0.05).Liver/kidney impairment was less in Obs(P<0.05). Conclusions Early evolocumab+ statin significantly lowers lipids, increases LDL-C goal attainment, reduces lipid variability, improves cardiac function/remodeling, and demonstrates better safety (less liver/kidney impairment) in ACS patients.